Chronic kidney disease and cardiovascular therapeutics: time to close the evidence gaps
- PMID: 21884955
- PMCID: PMC4109646
- DOI: 10.1016/j.jacc.2011.06.010
Chronic kidney disease and cardiovascular therapeutics: time to close the evidence gaps
Comment on
-
Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis.J Am Coll Cardiol. 2011 Sep 6;58(11):1152-61. doi: 10.1016/j.jacc.2011.04.041. J Am Coll Cardiol. 2011. PMID: 21884954
References
-
- National Kidney Foundation. . Part 4. Definition and classification of stages of chronic kidney disease. Am J Kidney Dis. 2002;39 (Suppl 1):S46–75.
-
- Abutaleb N. Why we should sub-divide CKD stage 3 into early (3a) and late (3b) components. Nephrol Dial Transplant. 2007;22:2728–9. - PubMed
-
- Kirsztajn GM, Suassuna JHR, Bastos MG. Dividing stage 3 of chronic kidney disease (CKD): 3a and 3b. Kidney Int. 2009;76:462–3. - PubMed
-
- National Kidney Foundation KDOQI Guidelines. [Accessed May 25, 2010];KDOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease [guidelines online] 2002 Available at: http://www.kidney.org/professionals/KDOQI/guidelines_bp/index.htm.
-
- Heywood JT, Fonarow GC, Costanzo MR, et al. for the ADHERE Scientific Advisory Committee and Investigators. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail. 2007;13:422–30. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
